

**WE CLAIM:**

- 1 1. A pharmaceutical composition comprising candesartan cilexetil and one or more  
2 fatty substances being present at a concentration of about 0.5% to about 10% w/w.
- 1 2. The pharmaceutical composition according to claim 1, wherein the fatty substances  
2 comprise lipids and phospholipids.
- 1 3. The pharmaceutical composition according to claim 2, wherein the lipids comprise  
2 fatty acids and fatty acid esters.
- 1 4. The pharmaceutical composition according to claim 3, wherein the fatty acids  
2 comprises one or more of lauric acid, myristic acid, stearic acid, palmitoleic acid, oleic  
3 acid, capric acid, caprylic acid, oleic acid, linoleic acid, arachidonic acid and mixtures  
4 thereof.
- 1 5. The pharmaceutical composition according to claim 3, wherein the fatty acid esters  
2 comprise one or more of glycerol stearate, glycerol palmitate, glyceryl caprate, glyceryl  
3 caprylate, glyceryl caprylate/ caprate, glycerol oleate, glycerol linoleate, glyceryl  
4 lauripalmitooleate and mixtures thereof.
- 1 6. The pharmaceutical composition according to claim 2, wherein the phospholipids  
2 comprise phosphoglycerides and sphingolipids.
- 1 7. The pharmaceutical composition according to claim 6, wherein the  
2 phosphoglycerides comprise one or more of lecithin, cephalin, soyalecithin, egglecithin,  
3 phosphatidylserine, phosphatidyl-inositol and mixtures thereof.
- 1 8. The pharmaceutical composition according to claim 1, wherein the candesartan  
2 cilexetil is present in a range of about 2% to about 35% w/w.
- 1 9. The pharmaceutical composition according to claim 1, wherein the composition  
2 further comprises one or more pharmaceutically acceptable excipients.

1 10. The pharmaceutical composition according to claim 9, wherein the one or more  
2 pharmaceutically acceptable excipients comprise one or more of fillers, binders,  
3 disintegrants, lubricants, coloring and flavoring agents.

1 11. The pharmaceutical composition according to claim 1, wherein the pharmaceutical  
2 composition is in the form of a tablet or a capsule.

1 12. The pharmaceutical composition according to claim 11, wherein the tablet further  
2 comprises a coating comprising one or more functional and/or non-functional layers.

1 13. A process for the preparation of a pharmaceutical composition, the process  
2 comprising:

3 dispersing candesartan cilexetil and one or more fatty substances at a concentration  
4 of about 0.5% to about 10%w/w in a binder solution to form a dispersion;

5 granulating the dispersion with one or more fillers and the one or more  
6 disintegrants to form granules; and

7 drying, sizing, lubricating and compressing the granules into tablets.

1 14. The process according to claim 13, wherein the dispersion further includes one or  
2 more fillers.

1 15. The process according to claim 13, wherein the dispersion further includes one or  
2 more disintegrants.

1 16. The process according to claim 13, wherein the granulation comprises wet  
2 granulation and/or dry granulation.

1 17. A method for the treatment of hypertension in a patient in need thereof, the method  
2 comprising administering a pharmaceutical composition comprising candesartan cilexetil  
3 and one or more fatty substances at a concentration of about 0.5% to about 10% w/w.

1 18. The method of treatment according to claim 17, wherein the fatty substances  
2 comprise lipids and phospholipids.

- 1 19. The method of treatment according to claim 17, wherein the candesartan cilexetil is
- 2 present in a range of about 2% to about 35% w/w.